Celcuity (CELC) announced that the first patient has been dosed in VIKTORIA-2, its Phase 3 clinical trial evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant. Gedatolisib is an investigational, multi-target PI3K/AKT/mTOR inhibitor that potently targets all four class I PI3K isoforms, mTORC1, and mTORC2 to induce comprehensive blockade of the PAM pathway.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity announces issuance of new patent for gedatolisib
- Promising Clinical Trial Results and Favorable Safety Profile Drive Buy Rating for Celcuity’s Gedatolisib
- Celcuity resumed with a Buy at Stifel
- Promising Preliminary Data and Positive Outlook for Celcuity’s Gedatolisib in Cancer Trials
- Celcuity Announces Promising Phase 1 Gedatolisib Results